ClinicalTrials.gg
CompletedNCT00236392Updated Nov 30, 2010

A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)

A Phase 3 interventional study of rabeprazole in Gastroesophageal Reflux and Heartburn, sponsored by Janssen Pharmaceutica N.V., Belgium. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-30.

Primary conditionNon-Erosive Reflux DiseaseRegistry: Gastroesophageal RefluxReclassifiedWhy we changed it
Registry
Gastroesophageal Reflux — the first condition term the registry derived for this study.
ClinicalTrials.gg
Non-Erosive Reflux Disease
Why
  1. The study's title name Non-Erosive Reflux Disease, a narrower term within Gastroesophageal Reflux.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Janssen Pharmaceutica N.V., Belgium (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
422
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the efficacy and safety of long-term, "on-demand" maintenance therapy with rabeprazole in patients with non-erosive reflux disease (NERD).

Read the detailed description

More than half of patients with typical gastroesophageal reflux symptoms such as heartburn are considered to have non-erosive reflux disease (NERD), which is characterized by a lack of clinically defined damage to the esophagus. One approach to maintain control of these symptoms is to have medication available "on-demand." This is a double-blind, placebo-controlled study of the effectiveness of "on-demand" rabeprazole in the long-term maintenance of heartburn control in NERD patients, for whom heartburn was resolved with short-term, daily rabeprazole therapy. The study has two phases: an acute phase (4 weeks) during which patients receive rabeprazole medication daily, and an "on-demand" phase (6 months) during which patients take medication (rabeprazole or placebo) as needed. Only patients who have complete resolution of heartburn at the end of the acute phase are eligible to continue in the "on-demand" phase. Efficacy assessments include the proportion of patients discontinuing treatment in the "on-demand" phase because of insufficient heartburn control, and the severity of heartburn and patient satisfaction determined at the beginning and end of "on-demand" phase. Safety assessments include incidence of adverse events throughout the study, physical examination at study initiation, and vital signs at the beginning and the end of the study. The study hypothesis is that "on-demand" therapy with rabeprazole is superior to placebo in maintaining heartburn control and is well tolerated by the patients with NERD. Rabeprazole tablet (10 milligrams[mg]) once daily in the morning for 4 weeks. Rabeprazole tablets (10mg) once daily on an "on-demand" basis for the following 6 months.

02

Conditions studied

  • Gastroesophageal Reflux
  • Heartburn

Browse trials for

Keywords

  • Gastroesophageal reflux
  • Heartburn
  • Rabeprazole
  • Anti-ulcer agents
  • GERD
  • Proton pump inhibitor
  • GORD
  • Non-Erosive Reflux Disease
  • NERD
03

In context

Non-Erosive Reflux Disease Reclassified

47 studies on the registry are indexed under Non-Erosive Reflux Disease; 8 are open to participants now.

This study's enrollment of 422 is above the median of 160 across 34 interventional studies indexed under Non-Erosive Reflux Disease.

Browse Non-Erosive Reflux Disease studies →

Lead sponsor

Janssen Pharmaceutica N.V., Belgium is the lead sponsor of 58 studies on the registry; none are open to participants now.

Compared within Non-Erosive Reflux Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gastroesophageal Reflux. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minimum of 12 months history of heartburn as the predominant symptom with at least 2 symptomatic episodes
  • Negative endoscopy (no erosive lesions according to the Modified Savary-Miller scale) within 7 days prior to acute treatment
  • at least 3 days with moderate to very severe heartburn within one week prior to acute treatment

Exclusion criteria

Exclusion Criteria:

  • No known gastro-duodenal ulcer
  • no infections, inflammations, or obstruction of the small or large intestine
  • no history of gastrointestinal cancer, or prior surgery of the stomach or intestine
  • no stomach or abdominal pain or discomfort as the predominant symptom or that requires treatment
  • no history of erosive reflux causing inflammation of the esophagus
  • no stricture of the esophagus, stomach, or any condition that causes difficulty in swallowing
  • no history of non-erosive reflux disease (NERD) that is or was to an adequate treatment course (1 month) with proton pump inhibitors
  • no females who are pregnant or those lacking adequate
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
422 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of patients discontinuing treatment in "on-demand" phase (6 months) because of insufficient heartburn control.

Secondary outcomes

  1. Severity and control of heartburn, overall quality of life (Psychological General Well-Being Index), antacid consumption, and patient satisfaction at the beginning and end of the "on-demand" phase. Incidence of adverse events throughout study

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Bytzer P, Blum A, De Herdt D, Dubois D; Trial Investigators. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004 Jul 15;20(2):181-8. doi: 10.1111/j.1365-2036.2004.01999.x. PubMed 15233698 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2001 and a completion of Oct 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2005
First posted
Oct 12, 2005
Start
Oct 2001
CompletionActual
Oct 2002
Last update
Nov 30, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00236392
First posted
Oct 12, 2005
Start date
Oct 2001
Completion
Oct 2002
Last update
Nov 30, 2010

Study contacts

Janssen Pharmaceutica N.V. Clinical Trial
study director · Janssen Pharmaceutica N.V.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion